Psyence Biomedical Settles Shareholder Litigation with KAOS Capital for $1.5M and Share Buyout

summarizeSummary

Psyence Biomedical Ltd. has reached a settlement with activist shareholder KAOS Capital, agreeing to pay $1.5 million and facilitate the sale of KAOS's 50,220 shares at a premium to resolve ongoing litigation and shareholder claims.

check_boxKey Events

• Settlement Reached

  Psyence Biomedical Ltd. settled a direct shareholder claim and related litigation with KAOS Capital Ltd. and Adam Arviv, resolving a dispute that began in January 2026.

• Significant Cash Payment

  The company agreed to pay KAOS Capital $1,500,000 USD in full and final settlement of all claims, a substantial financial commitment for the company.

• Share Disposition at Premium

  KAOS Capital will sell its entire holding of 50,220 common shares to a company-designated third party at $5.00 USD per share, which is a premium compared to the current market price of $2.92.

• Litigation Resolved and Standstill Agreement

  The settlement includes a full retraction of KAOS's allegations, a mutual release of claims, and a three-year standstill agreement preventing further activist actions by the KAOS Group.

auto_awesomeAnalysis

This settlement is a critical development for Psyence Biomedical, resolving a contentious shareholder dispute with KAOS Capital that involved litigation and allegations against the company. While the $1.5 million cash payment represents a substantial outflow for a company of this size, it removes significant legal and operational uncertainty. The agreement also includes the sale of KAOS's entire stake at a premium to the current market price, effectively removing an activist investor and securing a three-year standstill agreement, which should bring greater corporate stability. This follows a series of recent filings related to shareholder meetings and a reverse stock split, indicating a period of corporate restructuring and governance challenges. Investors should monitor the company's cash position and how this settlement impacts its operational runway.